Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies

This retrospective review evaluated our institutions’ practice of administering low fixed-dose FEIBA (high (1000 units) or low dose (500 units) for an INR ≥ 5 or <5, respectively) for the management of warfarin-associated coagulopathies. The primary outcome was the percentage of patients who had...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibarra, Francisco, Cruz, Mallory, Ford, Matthew, Wu, Meng-Jou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149897/
https://www.ncbi.nlm.nih.gov/pubmed/35645329
http://dx.doi.org/10.3390/pharmacy10030050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149897/
https://www.ncbi.nlm.nih.gov/pubmed/35645329
http://dx.doi.org/10.3390/pharmacy10030050

Ejemplares similares